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fewer than 6 months. CONCLUSIONS: These results
support the common belief that physicians differentially
prescribe SSRIs according to comorbid symptoms. Ob-
served differences in the prevalence of diagnoses across
SSRI therapies are consistent with differences in the range
of approved indications across drugs and preferential
prescribing of paroxetine for patients with comorbid
anxiety disorders.
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PRE-TREATMENT PATIENT DIFFERENCES: 
CHOICE OF DRUG THERAPY
WITHIN SCHIZOPHRENIA
Gibson PJ, Loosbrock DL
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OBJECTIVE: To examine pre-treatment differences in
characteristics of patients with schizophrenia treated
with olanzapine and risperidone, as reported in epidemi-
ologic studies. METHOD: All 15 non-randomized stud-
ies with olanzapine and risperidone cited in Medline or
presented at major conferences (APA, ECNP, WPA,
ISPOR) through 1999 were included. The direction, mag-
nitude, and statistical significance from all comparisons
of pre-treatment characteristics for schizophrenia pa-
tients initiating therapy on olanzapine or risperidone are
summarized. RESULTS: Several studies found olanzapine
patients were more likely to be younger and male. One of
six studies found younger mean age at onset, though
prior duration of illness results had no consistent direc-
tion. Other specific comparisons were included in only
one or two studies. History of hospital admission results
were mixed, though olanzapine patients had significantly
higher prior hospitalization costs in the one study with
that measure. Patients initiated on olanzapine were more
likely to have prior use of clozapine, depot antipsychot-
ics, and/or antidepressants, whereas patients initiated on
risperidone were more likely to have anticholinergic use
at therapy start. In one study, patients initiated on olan-
zapine had mean CGI scores and/or GAF scores indica-
tive of greater severity. CONCLUSIONS: When evalu-
ated, significant pre-treatment patient differences were
often found. Physicians may be choosing olanzapine ther-
apy for more complicated schizophrenic patients, indi-
cated by prior hospitalization cost, medication use, and
clinical assessment scores.
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OBJECTIVE: To determine how deficit syndrome relates
to patterns of antipsychotic drug use among persons with
schizophrenia receiving community-based care. METH-
ODS: Study participants were enrolled in the US Schizo-
phrenia Care and Assessment Program (SCAP). Data
were obtained from participants who completed the base-
line and 6-month assessments and were using antipsy-
chotic medications at baseline (n  1019). Presence of
deficit syndrome was assigned based on proxy methods
using clinical data (Kirkpatrick B., et al., 1989). Antipsy-
chotics were categorized as first-generation, second-gen-
eration, or other. Few participants received antipsychot-
ics in the ‘other’ category (2%) and were not included in
these analyses. Baseline characteristics and the presence
of deficit syndrome were used to predict two outcomes:
(1) the likelihood of receiving first-generation antipsy-
chotics at the initial assessment, and (2) the likelihood of
switching from one antipsychotic class to another be-
tween assessments. Covariates included demographic
(gender, race, age, marital status, education, insurance),
clinical (GAF, hallucinations/delusions, disorganization),
medication adherence, and site variables. Logistic regres-
sion was applied. RESULTS: Deficit syndrome was not
significantly related to use of a 1st-generation agent at
baseline. A positive association was found for African
Americans (.0004), lower hallucination/delusion scores
(.02), and several site indicators (.05) ( Orlando, Den-
ver, Baltimore, and San Diego). The probability of
switching antipsychotic classes between assessments was
significantly related to one site indicator (.01) (Orlando);
weak evidence (.08) of lower GAF scores being associ-
ated with a switch was observed. The presence of deficit
syndrome did not achieve significance in either model.
CONCLUSIONS: The deficit syndrome has been studied
extensively in its relation to neurological function and
course of illness. In the SCAP population of patients re-
ceiving community-based care at diverse settings, we do
not find a relation between deficit syndrome and two
measures of antipsychotic drug assignment. Further re-
search may include evaluation of the relationship be-
tween deficit syndrome and drug assignment patterns
over time.
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OBJECTIVES: The purpose of this study was to assess
the one-year direct schizophrenia-related treatment costs,
mental health care costs and total health care costs for
patients diagnosed with schizophrenia and initiating ther-
apy with either olanzapine or risperidone. METHODS: A
retrospective analysis of the integrated medical and phar-
macy claims of a large, geographically diverse, commer-
cially insured population was conducted. A previously
validated algorithm to identify schizophrenics was used
for patient selection. The confirmed schizophrenia pa-
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tients who began treatment with either olanzapine or ris-
peridone were included. Treatment course and associated
schizophrenia-related, mental health care and total health
care costs during the subsequent 12-month period were
examined using univariate and multivariate methods.
RESULTS: Nine hundred eighty-five (985) patients initi-
ated on risperidone and 348 initiated on olanzapine met
inclusion criteria. The mean dose was 4.02 and 10.49 for
risperidone and olanzapine patients, respectively. Patients
taking olanzapine versus risperidone stayed on therapy
longer during the 12-month observation period (217 days
versus 181 days, p  0.0001). Although pharmaceutical
costs were significantly higher for olanzapine patients,
their medical costs were significantly lower than those on
risperidone. After adjusting for differences in patient de-
mographics, disease severity and comorbidities, olanza-
pine patients had significantly lower mental health care
costs including drug costs ($1,827 less, p  0.05) and
lower total health care costs ($1,834 less, p  0.05). The
schizophrenia-related costs (including drug costs) were
not statistically significantly different, though numeri-
cally the risperidone patients incurred $740 more per pa-
tient than patients on olanzapine (p  0.26). CONCLU-
SIONS: The findings in this study suggest that the initial
selection of atypical antipsychotic for the treatment of
schizophrenia matters, as olanzapine offset its acquisition
cost by reducing medical costs and demonstrated signifi-
cant mental and total health care cost savings over ris-
peridone.
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OBJECTIVES: The Positive And Negative Syndrome
Scale (PANSS) and Calgary Depression Scale for Schizo-
phrenics (CDSS) are widely used in the evaluation of
schizophrenia. Their internal validity have already been
evaluated with classical methods (multitrait and confir-
matory analyses). During the last two decades, Item Re-
sponse Theory has been developed to deal with latent
traits. As part of it, Rasch models are commonly used in
Quality of Life research but not yet for other outcome
questionnaires. METHODS: 458 schizophrenic patients
were evaluated with the PANSS and CDSS. Rasch models
for polytomous items were fitted to the data in order to
assess: 1) unidimensionality of the CDSS and the PANSS
subscales, i.e. their ability to measure one latent trait (de-
gree of depression/degree of positive, negative, general
schizophrenic symptoms); infit and outfit statistics were
used and residuals studied; 2) invariance of comparisons,
implying that the parameter characterizing an item does
not depend on the latent trait distribution of the popula-
tion; item parameters estimates were compared for two
subgroups of the population. RESULTS: Unidimension-
ality and invariance of comparisons are globally satisfac-
tory for the CDSS, although the appropriateness of two
items (items four and seven) may be questionable. Results
do not support the three-dimensional structure for the
PANSS, which is commonly used as the reference. CON-
CLUSIONS: Further investigation of the factorial struc-
ture of PANSS (e.g five-factors structures, which have
been proposed by several authors) is necessary. Rasch
models provide a powerful approach to evaluate internal
validity of mental health scales, enabling to investigate
invariance of comparisons, which constitutes the major
distinction from classical methods.
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OBJECTIVES: Health economic assessment of cost-effec-
tiveness parameters for the comparison of typical (Halo-
peridol), partially atypical depot (Flupentixol) and atypi-
cal neuroleptics (Olanzapin, Risperidon) in the treatment
of schizophrenia from the perspective of German health
insurance. METHODS: A published markov model was
rebuilt and calibrated with DATA®, taking into consid-
eration relapse rates, extrapyramidal symptoms (EPS)
and other prognostic symptoms. All data were derived
from published sources where available. Besides the com-
parison of monotherapy, a stepwise treatment scenario
was simulated, starting with three months Olanzapin
treatment followed by Flupentixol. Over the 5-year simu-
lation period cumulated complication rates (percentage
of relapse, positive and negative symptoms), patient re-
lated outcomes (Brief Psychiatric Rating Score “BPRS”)
and cost parameters (medication, EPS-cost and total
costs) were assessed. A cost-effectiveness analysis was
performed. RESULTS: Olanzapin/Flupentixol in combi-
nation had the lowest relapse rate (42.9 %), followed by
Flupentixol (44.4%), Olanzapin (44.8%), Risperidon
(48.0 %) and Haloperidol (57.6%). Olanzapin treatment
showed the highest BPRS score (3.13), followed by Ris-
peridon (3.07), Olanzapin/Flupentixol (2.52), Flupen-
tixol (2.42) and Haloperidol (2.37). The most cost-effec-
tive treatment measured by cost in DEM per relapse free
patient was Olanzapin/Flupentixol (200,000), followed
by Olanzapin (211,000), Flupentixol (212,000), Risperi-
don (231,000) and Haloperidol (287,000). The best cost-
effectiveness (expressed in DEM/BPRS) was observed in
Olanzapin (37,100), followed by Risperidon (39,100),
Olanzapin/Flupentixol (45,500), Flupentixol (48,600)
and Haloperidol (51,400). Total 5-year drug cost (DEM)
